NHLBI Announces Small Business Topics of Special Interest (TOSI)

Notice Number: NOT-HL-15-282

Key Dates
Release Date: November 10, 2015  

Related Announcements

Issued by
National Heart, Lung, and Blood Institute (NHLBI)


NHLBI announces Small Business Topics of Special Interest (TOSI) that are of high programmatic interest. The Small Business TOSI listing may be accessed at http://www.nhlbi.nih.gov/research/funding/sbir/funding-opportunities/omnibus_grant_solicitation.htm.

TOSI will change periodically as Institute programmatic interests dictate. These topics are not formal announcements for applications (Funding Opportunity Announcements). Although funds are not set aside for awards on these topics, applications submitted in response to TOSI are eligible for special funding consideration. TOSI applications will be peer reviewed by SBIR/STTR study sections at the NIH Center for Scientific Review (CSR).

Small business applicants may submit investigator-initiated applications through any of the Omnibus Funding Opportunity Announcements:

  • Small Business Technology Transfer (STTR) - R41/R42 - PA-15-270
  • Small Business Innovation Research (SBIR) - R43/R44 - PA-15-269
  • Direct Phase II SBIR Grants to Support Biomedical Technology Development (SBIR) - R44 - PAR-14-088

Investigators interested in developing applications for these topics are encouraged to discuss their ideas with the NHLBI Small Business Coordinator Jennifer Shieh (nhlbi_sbir@mail.nih.gov).

Applications submitted in response to the Omnibus Grant Funding Opportunity Announcements  are not limited to the research and development areas described below.


Instructions for submitting applications:
At the beginning of the title, please include the following four characters: HLS- 
Please note that NIH limits title character length to 200 characters including the spaces between words and punctuation.

In the first sentence of the abstract, please include the code shown in the last column of the table below. This coding is for internal NHLBI tracking purposes only.




Animal and Cellular Models:
for rare non-malignant and  pre-malignant (MDS & MPD) hematologic disorders
for complications associated with thrombosis
for transfusion of blood products or cell-based  therapies


Research tools:  Imaging, reagents, assays including microassays, microfluidics, bioinformatics and nanotechnology for investigations of blood diseases, transfusion and cellular therapies 


Diagnostics: devices, biomarkers, imaging, and assays for non-malignant blood disorders 


Therapeutics:  drugs, blood product and cellular therapies, and gene therapy for non-malignant blood disorders 


E-medicine Apps for patients and medical professionals to improve the management of and reduce the impact of non-malignant blood diseases 


Development of molecular imaging reagents/techniques and nanotechnology-based drug delivery systems which would detect and then allow for specific targeting of lung diseases, such as plexiform lesions in PAH and/or microvascular loci susceptible to rarefaction/pruning in obstructive airway diseases like emphysema, or fibrotic triggers in IPF.


Development of reagents and methods to identify and isolate stem/progenitor cells, and direct differentiation to specific functional organ units. These reagents may include antibodies for stem/progenitor cell detection and sorting, biomaterials for optimizing the microniches of stem/progenitor cells, as well as methods for 3-D regeneration of tissue.


Development and validation of techniques(or algorithms) to study the microbiome in situ, including, but not limited to:
Sampling the microbiome of different lung or gut segments while minimizing contamination from other locations.
Development of an analytical system to study the metabolic products of the lung and gut microbiome from breath condensate


Characterization and in vivo / in vitro applications of miRNA panels that target lung-resident mesenchymal or fibroblast cells and promote directly or indirectly lung repair/regeneration


Development of high throughput methods to apply microfluidics technology in discovery of molecular profiles (DNAs, RNAs, proteins, or metabolites) in a large number of sputum or exhaled breath condensate samples collected from lung disease patients.  


Develop a biocompatible fluid sealant and associated transcatheter technique to permanently seal paravalvular leaks resulting from transcatheter cardiac valve replacement


Develop smart phone apps and other communication tools to increase accessibility and evaluation of the latest educational materials and trial research on cardiovascular, nutritional and physical activity information for medical professionals and patients (English and non-English speakers)


Develop a technology that enables immediate, user-friendly measures of average daily sodium intake. These technologies would replace the current standard of 24-hour urine collection


New animal models for the study of chronic venous insufficiency (CVI) and post-thrombotic syndrome, and innovative approaches for their prevention and treatment.


Development of mechanical circulatory support devices for individuals with congenital heart disease and single ventricle physiology after Fontan surgical palliation.    


Novel non-invasive strategies that detect early subclinical changes in cardiac structure, function, and /or tissue are needed to improve detection and monitoring of chemotherapy-induced cardiac injury in order to improve cardioprotection and effectiveness of cancer therapeutics.  Strategies that increase sensitivity and precision of existing or enhance imaging technologies with respect to normal and altered cardiac structure, function, energetics, and metabolism are sought.  Pre-clinical or patient studies using molecular changes or biomarkers to enhance early detection of cardiac derangements are also responsive.


Develop innovative technology and/or service delivery model or design targeted at increasing the adoption, uptake, and sustainability of evidence-based guideline recommendation for the management of heart, lung, blood, and sleep disorders, that include multi-level (health systems, provider, and patient) facets and benefit ethnic/racial minority groups, rural populations, and low socioeconomic groups.



Please direct all inquiries to:

Jennifer Shieh, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-2149
Email: nhlbi_sbir@mail.nih.gov

The NHLBI Office of Translational Alliances and Coordination (OTAC) offers assistance to applicants and awardees regarding regulatory approval, commercialization, and business plan development. NHLBI OTAC also hosts Small Biz Hangouts, a free educational series covering the basics of biomedical technology development. Archived events can be found on the NHLBI YouTube channel (http://bit.ly/SmallBizHangouts-YouTube). Sign up for the NHLBI listserv (http://bit.ly/NHLBI-SBIR-list) and visit our website (http://www.nhlbi.nih.gov/sbir) to learn about upcoming events and available resources.